Novartis Australia Pty Ltd

Regulatory activities for this sponsor.

4 result(s) found, displaying 1 to 4

AusPAR: Erenumab

10 September 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Erenumab
AusPAR: Omalizumab (rch)

22 June 2016

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Omalizumab (rch)
AusPAR: Ruxolitinib

21 January 2014

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ruxolitinib
AusPAR: Zoledronic acid

31 August 2011

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Zoledronic acid